82
Participants
Start Date
August 22, 2018
Primary Completion Date
August 30, 2026
Study Completion Date
August 30, 2029
T-DM1
T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
Memorial Sloan Kettering Cancer Center, New York
University of North Carolina, Chapel Hill
Rex Cancer Center, Raleigh
Sarah Cannon Research Institute, Nashville
Mayo Clinic, Rochester
City of Hope Comprehensive Cancer Center, Duarte
The Stamford Hospital, Stamford
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth
Dana-Farber/New Hampshire Oncology-Hematology, Londonderry
Lifespan Cancer Institute, Providence
Susan G. Komen Breast Cancer Foundation
OTHER
Gateway for Cancer Research
OTHER
Dana-Farber Cancer Institute
OTHER